Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial.
Makaleler > Tam Makale · 2018
Yazarlar: Griesshammer Mİ, Güray SAYDAM, FR PALANDİRİ, Gİ BENEVOLO, MA EGYED, JE CALLUM, Tİ DEVOS, Serdar ŞIVGIN, PA GUGLİELMELLİ, CE BENSASSON, MU KHAN, JP RONJO, FR PASSAMONTİ
Ann Hematol, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Social Sciences Citation Index, 2018, cilt 98, ss 1591-1600